Skip to main content

Table 1 Drugs obtained and their biological targets

From: Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis

Scorea Biological target Action Drugs p value
+ Topoisomerase II Inhibitor Amsacrine, amonafide, teniposide, etoposide, idarubicin 2.829 × 10–4
+ HDAC Inhibitor Panobinostat, scriptaid, dacinostat, vorinostat, trichostatin A 1.451 × 10–4
+ Protein kinase C delta Activator Phorbol-12-myristate-13-acetate, ingenol 3.172 × 10–3
+ Histone lysine methyltransferase Inhibitor Chaetocin  
+ ARFGAP1 Inhibitor QS11  
+ PDK1 Inhibitor BX795  
+ Retinoic acid receptor beta Inhibitor Le135  
+ Arginase Inhibitor Inhibitor Bec  
+ JAK2/STAT3 Inhibitor Cucurbitacin I  
+ Fatty acid synthetase Inhibitor Cerulenin  
+ Src, Bcr-Abl tyrosine kinase Inhibitor AG957  
+ PLD2 Inhibitor CAY10594  
+ IKKβ Inhibitor Parthenolide  
+ IMPDH1 Inhibitor Mycophenolic acid  
+ FTL3 Inhibitor Midostaurin  
+ DNA Crosslinker Mitomycin C  
+ Tubulin Inhibitor Vinblastine  
+ Hsp90 Inhibitor Radicol  
+ Multiple targets Inhibitor Resveratrol  
PI3K Inhibitor PI828, GDC0941, NVP-BEZ235,PP110, TGX115 4.915 × 10–6
mTOR Inhibitor NVP-BEZ235, AZD8055, TGX115, Ku0063794 1.792 × 10–5
CDK Inhibitor BML259, indirubin 1.463 × 10–2
IKBalfa Inhibitor Evodiamine  
Farnesyltransferase Inhibitor Tipifarnib  
IGF1R Inhibitor Linsitinib  
MAP2K1 Inhibitor Selumetinib  
CHK1 Inhibitor SB218078  
Piruvate kinase Inhibitor M2PK activator  
Rho kinase Inhibitor Rho kinase inhibitor III  
Voltage-dependent calcium channel Inhibitor Nifedipine  
Braf Inhibitor Vemurafenib  
  1. Table presents significant drugs with their biological target and their mechanism of action. p value calculated for groups of drugs with the same target using Fisher’s exact test
  2. CDK cyclin-dependent kinase, HDAC histone deacetylase, mTOR mammalian target of rapamycin, PI3K phosphoinositol 3 kinase
  3. a+ drugs with positive similarity score, drugs with negative similarity score in regard to SLE signatures